Localized Subcutaneous Acute Febrile Neutrophilic Dermatosis in a Dog

Table 1

Protocol of the administered drugs during hospitalization of the dog. All listed drugs were administered from the day of presentation onwards, unless mentioned otherwise.

Drug ingredient	Dose and form of application	Duration of application
Antibiotics
Enrofloxacina	11 mg/kg per os (PO) q 12 hr	6 weeks
Amoxicillin/clavulanic acidb	20 mg/kg intravenously (IV) q 8 hr	5 weeks
Amoxicillin/clavulanic acidc	12.5 mg/kg PO q 12 hr	2 weeks (following IV administration)
Metronidazoled	15 mg/kg IV q 12 hr	1 week
Glucocorticoids
Dexamethasonee	0.15 mg/kg IV q 12 hr	6 days
Prednisolonef	2 mg/kg PO q 24 hr	2 weeks (following dexamethasone), then gradually tapered over 4 weeks
Analgesics
Fentanylg	2.5–7.5 μg/kg/hr constant rate infusion (CRI)	10 days
Ketamineh	10 μg/kg/hr CRI	8 days
Buprenorphinei	0.01-0.02 mg/kg subcutaneously q 8 hr	3 weeks
Tramadolj	3 mg/kg PO q 8 hr	3 weeks
Gastric protection
Omeprazolek	1 mg/kg PO q 24 hr	7 weeks
Sucralfatel	30 mg/kg PO q 12 hr	10 days
Metoclopramidem	0.2 mg/kg IV q 6 hr	10 days
Dolasetronen	0.5 mg/kg q 24 hr	7 days
Fluid therapy
Full electrolyte solutiono	1–4 mL/kg/hr CRI	4 weeks

aBaytril 2.5%, Provet AG, Lyssach, Switzerland; bAugmentin Adult, Glaxosmithkline, Muenchenbuchsee, Switzerland; cClavaseptin, Vetoquinol AG, Ittigen, Switzerland; dMetronidazol B. Braun, B. Braun Medical AG, Sempach, Switzerland; eDexatat, Dr. E. Graeub AG, Bern, Switzerland; fPrednisolon Streuli, G. Streuli & Co. AG, Uznach, Switzerland; gSintenyl i.v. 0.5 mg, Sintetica S.A., Mandrisio, Switzerland; hKetasol, Dr. E. Graeub AG, Bern, Switzerland; iTemgesic, Essex Pharma GmbH, Munich, Germany; jTramadol-Mepha 50 retard, Mepha Pharma AG, Aesch, Switzerland; kOmeprazol-Teva, Teva Pharma AG, Aesch, Switzerland; lUlcogant Suspension, Merck Serono GmbH, Darmstadt, Germany; mPaspertin, Abbott, Altishofen, Switzerland; nAnzemet, Sanofi-Aventis; Meyrin, Switzerland; oPlasma-Lyte A, Baxter AG, Volketswil, Switzerland.